Search Result

Results for "

malignant gliomas

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) c-Met/HGFR (1) Cadherin (1) Carbonic Anhydrase (1) Cytochrome P450 (4) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (2) Endogenous Metabolite (4) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (1) HIV (4) HIV Protease (4) Isotope-Labeled Compounds (1) Liposome (1) MMP (1) P-glycoprotein (4) PI3K (1) PKA (1) PROTAC Linkers (1) Ras (2) Reactive Oxygen Species (ROS) (1) Reference Standards (2) SARS-CoV (4) TNF Receptor (1) Toll-like Receptor (TLR) (3)
By Research Areas:	Cancer (16) Cardiovascular Disease (3) Infection (4) Inflammation/Immunology (1) Neurological Disease (1)

By Targets:

Apoptosis (4)

c-Met/HGFR (1)

Cadherin (1)

Carbonic Anhydrase (1)

Cytochrome P450 (4)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (2)

Endogenous Metabolite (4)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Acetyltransferase (1)

HIV (4)

HIV Protease (4)

Isotope-Labeled Compounds (1)

Liposome (1)

MMP (1)

P-glycoprotein (4)

PI3K (1)

PKA (1)

PROTAC Linkers (1)

Ras (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

SARS-CoV (4)

TNF Receptor (1)

Toll-like Receptor (TLR) (3)

By Research Areas:

Cancer (16)

Cardiovascular Disease (3)

Infection (4)

Inflammation/Immunology (1)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)	Infection Cardiovascular Disease Cancer
Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)	Infection Cardiovascular Disease Cancer
Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor with blood-brain barrier permeability. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-15735

c-Met inhibitor 1 1 Publications Verification	c-Met/HGFR	Cancer
c-Met inhibitor 1 is an orally active c-Met inhibitor. c-Met inhibitor 1 can inhibit c-Met phosphorylation with an IC₅₀ of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma .

HY-13440

AMG 511 5 Publications Verification	PI3K	Cancer
AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks, with K_is of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3K signaling that is indicated by p-Akt (Ser473) decrease. AMG 511 exhibits anti-tumor activity in mouse glioblastoma xenograft model .

HY-W156324

Biotin-PEGn-NHS ester	PROTAC Linkers Liposome	Others
Biotin-PEGn-NHS ester is a biotin-labeled PROTAC linker, which belongs to the PEG class and can be used to synthesize PROTAC molecules. Biotin-PEGn-NHS ester can interact with free neutral avidin in solution and successfully target malignant glioma cells. Biotin-PEGn-NHS ester can also be grafted onto the amino group of GelMA to prepare biotin-modified functionalized hydrogel, gelatin methacryloyl (Bio-GelMA) .

HY-102078

ZINC69391 1 Publications Verification	Ras Apoptosis	Cancer
ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects .

HY-B0764B

Bucladesine Dibutyryl cAMP; DBcAMP	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-123009

KCN1	HIF/HIF Prolyl-Hydroxylase Histone Acetyltransferase	Cancer
KCN1 is a p300/HIF-1α interaction inhibitor. KCN1 inhibits HIF transcriptional activity by binding to the CH1 domain of p300 and preventing the p300/HIF-1α assembly. KCN1 exerts antitumor activities through cell cycle arrest .

HY-P99772

Onfekafusp alfa L19TNF	TNF Receptor	Cancer
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .

HY-175291

Cystatin B agonist 1	MMP Cadherin	Cancer
Cystatin B agonist 1 is an orally active MMP-2/9 inhibitor. Cystatin B agonist 1 exhibits inhibitory effects with IC₅₀ values of 3.95 and 3.43 μM against U87 and T98G cells, respectively. Cystatin B agonist 1 induces the cell-cycle arrest at S phase, inhibits angiogenesis, and suppresses migration and invasion of MG cells. Cystatin B agonist 1 inhibits tumor growth in U87 MG xenograft model. Cystatin B agonist 1 can be used for the study of malignant glioma (MG) .

HY-173116

DOTA-XYIMSR-01	Carbonic Anhydrase	Cancer
DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy .

HY-119916

Tauromustine	DNA/RNA Synthesis	Cancer
Tauromustine is an orally active nitrosourea anticancer agent. Tauromustine has an alkylation effect and can damage the DNA function. Tauromustine has a high therapeutic index, especially in the study of Walker 256 rat sarcoma. It is also active against melanoma, breast cancer, pleural mesothelioma and ovarian cancer. Tauromustine is mainly metabolized in the liver, but some of its metabolites also have cytotoxicity .

HY-17367R

Atazanavir (Standard) BMS-232632 (Standard)	Reference Standards HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367S5

Atazanavir-d24 BMS-232632-d₂₄	Isotope-Labeled Compounds P-glycoprotein SARS-CoV Endogenous Metabolite HIV Cytochrome P450 HIV Protease Toll-like Receptor (TLR)	Infection Cardiovascular Disease Cancer
Atazanavir-d₂₄ (BMS-232632-d₂₄) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-106435

Cystemustine	DNA/RNA Synthesis DNA Alkylator/Crosslinker	Cancer
Cystemustine is a DNA inhibitor (a chloroethyl nitrosourea, CENU). Cystemustine can cause DNA cross-linking, thereby inhibiting the proliferation of tumor cells. Cystemustine can also exert cytotoxic effects by interfering with the cell cycle, inducing cell re-differentiation, and altering phospholipid metabolism. Cystemustine exhibits high anti-tumor activity and a relatively short plasma half-life in mice. Cystemustine can be used for the study of various malignant tumors, including melanoma, glioma, renal cancer, head and neck cancer, and colorectal cancer, etc .

HY-102078R

ZINC69391 (Standard)	Reference Standards Ras Apoptosis	Cancer
ZINC69391 (Standard) is the analytical standard of ZINC69391 (HY-102078). This product is intended for research and analytical applications. ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects .

HY-182436

MINA53-IN-1	Apoptosis	Cancer
MINA53-IN-1 is a selective MINA53 inhibitor with an IC₅₀ of 1.5 μM. MINA53-IN-1 induces DNA damage, cell cycle arrest and apoptosis in tumor cells. MINA53-IN-1 can be used for cancer research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99772

Onfekafusp alfa L19TNF	TNF Receptor	Cancer
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)
Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)
Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor with blood-brain barrier permeability. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367R

Atazanavir (Standard) BMS-232632 (Standard)	Structural Classification Alkaloids Pyridine Alkaloids Endogenous metabolite Source Classification	Reference Standards HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

Cat. No.	Product Name	Chemical Structure

HY-17367S5

Atazanavir-d24
Atazanavir-d₂₄ (BMS-232632-d₂₄) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

Atazanavir-d24

Atazanavir-d₂₄ (BMS-232632-d₂₄) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks